Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours

BACKGROUND: We conducted a phase I study in patients with advanced solid tumours to identify the recommended dose, assess pharmacokinetics (PK), pharmacodynamic activity and preclinical antitumour efficacy of the combination of sirolimus and gemcitabine. METHODS: Nineteen patients were treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin-Liberal, J, Gil-Martín, M, Sáinz-Jaspeado, M, Gonzalo, N, Rigo, R, Colom, H, Muñoz, C, Tirado, O M, García del Muro, X
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150275/
https://www.ncbi.nlm.nih.gov/pubmed/25003665
http://dx.doi.org/10.1038/bjc.2014.370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150275/
https://www.ncbi.nlm.nih.gov/pubmed/25003665
http://dx.doi.org/10.1038/bjc.2014.370

Ejemplares similares